Probucol Release from Novel Multicompartmental Microcapsules for the Oral Targeted Delivery in Type 2 Diabetes
In previous studies, we developed and characterised multicompartmental microcapsules as a platform for the targeted oral delivery of lipophilic drugs in type 2 diabetes (T2D). We also designed a new microencapsulated formulation of probucol-sodium alginate (PB-SA), with good structural properties an...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
AAPS
2014
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/20.500.11937/5324 |
| _version_ | 1848744765335535616 |
|---|---|
| author | Mooranian, Armin Negrulj, Rebecca Al-Sallami, H. Fang, Zhongxiang Mikov, Momir Golocorbin-Kon, S. Fakhoury, M. Watts, G. Matthews, V. Arfuso, Frank Lambros, Amanda Al-Salami, Hani |
| author_facet | Mooranian, Armin Negrulj, Rebecca Al-Sallami, H. Fang, Zhongxiang Mikov, Momir Golocorbin-Kon, S. Fakhoury, M. Watts, G. Matthews, V. Arfuso, Frank Lambros, Amanda Al-Salami, Hani |
| author_sort | Mooranian, Armin |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | In previous studies, we developed and characterised multicompartmental microcapsules as a platform for the targeted oral delivery of lipophilic drugs in type 2 diabetes (T2D). We also designed a new microencapsulated formulation of probucol-sodium alginate (PB-SA), with good structural properties and excipient compatibility. The aim of this study was to examine the stability and pH-dependent targeted release of the microcapsules at various pH values and different temperatures. Microencapsulation was carried out using a Büchi-based microencapsulating system developed in our laboratory. Using SA polymer, two formulations were prepared: empty SA microcapsules (SA, control) and loaded SA microcapsules (PB-SA, test), at a constant ratio (1:30), respectively. Microcapsules were examined for drug content, zeta potential, size, morphology and swelling characteristics and PB release characteristics at pH 1.5, 3, 6 and 7.8. The production yield and microencapsulation efficiency were also determined. PB-SA microcapsules had 2.6 ± 0.25% PB content, and zeta potential of −66 ± 1.6%, suggesting good stability. They showed spherical and uniform morphology and significantly higher swelling at pH 7.8 at both 25 and 37°C (p < 0.05). The microcapsules showed multiphasic release properties at pH 7.8. The production yield and microencapsulation efficiency were high (85 ± 5 and 92 ± 2%, respectively). The PB-SA microcapsules exhibited distal gastrointestinal tract targeted delivery with a multiphasic release pattern and with good stability and uniformity. However, the release of PB from the microcapsules was not controlled, suggesting uneven distribution of the drug within the microcapsules. |
| first_indexed | 2025-11-14T06:06:40Z |
| format | Journal Article |
| id | curtin-20.500.11937-5324 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T06:06:40Z |
| publishDate | 2014 |
| publisher | AAPS |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-53242019-02-19T05:35:28Z Probucol Release from Novel Multicompartmental Microcapsules for the Oral Targeted Delivery in Type 2 Diabetes Mooranian, Armin Negrulj, Rebecca Al-Sallami, H. Fang, Zhongxiang Mikov, Momir Golocorbin-Kon, S. Fakhoury, M. Watts, G. Matthews, V. Arfuso, Frank Lambros, Amanda Al-Salami, Hani diabetes mellitus artificial-cell microencapsulation anti-inflammatory probucol antioxidant type 2 diabetes In previous studies, we developed and characterised multicompartmental microcapsules as a platform for the targeted oral delivery of lipophilic drugs in type 2 diabetes (T2D). We also designed a new microencapsulated formulation of probucol-sodium alginate (PB-SA), with good structural properties and excipient compatibility. The aim of this study was to examine the stability and pH-dependent targeted release of the microcapsules at various pH values and different temperatures. Microencapsulation was carried out using a Büchi-based microencapsulating system developed in our laboratory. Using SA polymer, two formulations were prepared: empty SA microcapsules (SA, control) and loaded SA microcapsules (PB-SA, test), at a constant ratio (1:30), respectively. Microcapsules were examined for drug content, zeta potential, size, morphology and swelling characteristics and PB release characteristics at pH 1.5, 3, 6 and 7.8. The production yield and microencapsulation efficiency were also determined. PB-SA microcapsules had 2.6 ± 0.25% PB content, and zeta potential of −66 ± 1.6%, suggesting good stability. They showed spherical and uniform morphology and significantly higher swelling at pH 7.8 at both 25 and 37°C (p < 0.05). The microcapsules showed multiphasic release properties at pH 7.8. The production yield and microencapsulation efficiency were high (85 ± 5 and 92 ± 2%, respectively). The PB-SA microcapsules exhibited distal gastrointestinal tract targeted delivery with a multiphasic release pattern and with good stability and uniformity. However, the release of PB from the microcapsules was not controlled, suggesting uneven distribution of the drug within the microcapsules. 2014 Journal Article http://hdl.handle.net/20.500.11937/5324 10.1208/s12249-014-0205-9 AAPS fulltext |
| spellingShingle | diabetes mellitus artificial-cell microencapsulation anti-inflammatory probucol antioxidant type 2 diabetes Mooranian, Armin Negrulj, Rebecca Al-Sallami, H. Fang, Zhongxiang Mikov, Momir Golocorbin-Kon, S. Fakhoury, M. Watts, G. Matthews, V. Arfuso, Frank Lambros, Amanda Al-Salami, Hani Probucol Release from Novel Multicompartmental Microcapsules for the Oral Targeted Delivery in Type 2 Diabetes |
| title | Probucol Release from Novel Multicompartmental Microcapsules for the Oral Targeted Delivery in Type 2 Diabetes |
| title_full | Probucol Release from Novel Multicompartmental Microcapsules for the Oral Targeted Delivery in Type 2 Diabetes |
| title_fullStr | Probucol Release from Novel Multicompartmental Microcapsules for the Oral Targeted Delivery in Type 2 Diabetes |
| title_full_unstemmed | Probucol Release from Novel Multicompartmental Microcapsules for the Oral Targeted Delivery in Type 2 Diabetes |
| title_short | Probucol Release from Novel Multicompartmental Microcapsules for the Oral Targeted Delivery in Type 2 Diabetes |
| title_sort | probucol release from novel multicompartmental microcapsules for the oral targeted delivery in type 2 diabetes |
| topic | diabetes mellitus artificial-cell microencapsulation anti-inflammatory probucol antioxidant type 2 diabetes |
| url | http://hdl.handle.net/20.500.11937/5324 |